Identification of ROS1 rearrangement in gastric adenocarcinoma

Cancer

Volumn 119, Issue 9, 2013, Pages 1627-1635

  Lee, Jeeyun ^a   Lee, Seung Eun ^a   Kang, So Young ^a   Do, In Gu ^b   Lee, Sujin ^a   Ha, Sang Yun ^a   Cho, Jeonghee ^b   Kang, Won Ki ^a   Jang, Jiryeon ^a   Ou, Sai Hong Ignatius ^c   Kim, Kyoung Mee ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

crizotinib; driver mutation; fluorescence in situ hybridization; molecularly target therapy; ROS1 inhibitors; ROS1 rearranged gastric adenocarcinoma; SLC34A2 ROS1

Indexed keywords

SODIUM DIHYDROGEN PHOSPHATE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HER2 GENE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MET GENE; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROS1 GENE; SLC34A2 GENE; STOMACH ADENOCARCINOMA; TISSUE DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS;

EID: 84876666653     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27967     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012; 61: 673-684.
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376: 687-697.
4. Charest A, Lane K, McMahon K, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(q21q21). Gene Chromosomes Cancer. 2003; 37: 58-71.
5. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-1203.
6. Bergethon K, Shaw AT, Ou S-HI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012; 30: 863-870.
7. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18: 378-381.
8. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012; 18: 4449-4457.
9. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012; 18: 4570-4579.
10. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012; 150: 1121-1134.
11. Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma [serial online]. PLoS One. 2011; 6: e15640.
12. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract 7508.
13. Acquaviva J, Wong R, Charest A,. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009; 1795: 37-52.
14. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer. 2012; 118: 4427-4436.
15. Cho EY, Choi YL, Han JJ, et al. Expression and amplification of HER2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathol Int. 2008; 58: 17-25.
16. Ruschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012; 25: 637-650.
17. Spigel DR, Ervin TJ, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract 7505.
18. Pao W, Hutchison KE,. Chipping away at the lung cancer genome. Nat Med. 2012; 18: 349-351.
19. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18: 382-384.
20. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res. 2009; 7: 1466-1476.
21. Zhang ZJ, Ong CK, Cutcutache I, et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res. 2011; 71: 29-39.
22. Yamashita S, Nomoto T, Abe M, Tatematsu M, Sugimura T, Ushijima T,. Persistence of gene expression changes in stomach mucosae induced by short-term N-methyl-N′-nitroso guanidine treatment and their presence in stomach cancers. Mutat Res. 2004; 549: 185-193.
23. Murer H, Forster I, Biber J,. The sodium phosphate cotransporter family SLC34. Pflugers Arch Eur J Physiol. 2004; 447: 763-767.
24. Hilfiker H, Hattenhauer O, Traevert M, Forster I, Murer H, Biber J,. Characterization of a murine type II sodium-phosphate cotransporter expressed in mammalian small intestine. Proc Natl Acad Sci U S A. 1998; 95: 14564-16569.
25. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB,. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012; 7: 1086-1090.
26. Janne PA, Meyerson M,. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol. 2012; 30: 878-879.